Consequently, the combined strategy of Grp94 inhibition and FBXL2 activation has been shown to exert potent growth-suppressive effects in EGFR-TKI-resistant NSCLC models [57]. The gene discussed is FBXL2; the disease is non-small cell lung carcinoma.